G007-LK Tankyrase 1/2 Inhibitor: Precision Tool for Wnt/β-Catenin and Cancer Biology

Executive Summary: G007-LK is a potent, selective small-molecule inhibitor of tankyrase 1 and 2, with IC₅₀ values of 46 nM and 25 nM respectively, enabling precise suppression of poly(ADP-ribosyl)ation in cell and animal models (Jia et al., 2017). It efficiently inhibits Wnt/β-catenin signaling in APC-mutant colorectal cancer cells, inducing β-catenin degradation and AXIN1/2 stabilization (APExBIO). In in vivo xenograft models, G007-LK reduces tumor growth and β-catenin protein levels, supporting its use in translational research (Jia et al., 2017). Solubility, storage, and workflow guidelines optimize its application, with a recommended concentration of ≥26.5 mg/mL in DMSO. G007-LK is widely adopted for dissecting Wnt/β-catenin, Hippo/YAP, and related cancer signaling pathways.

Biological Rationale

Tankyrases (TNKS1, TNKS2) are poly(ADP-ribose) polymerases (PARPs) that regulate protein turnover in Wnt/β-catenin signaling, telomere maintenance, and cell cycle progression (Jia et al., 2017). Aberrant tankyrase activity promotes β-catenin stabilization, driving tumorigenesis in colorectal and hepatocellular cancers. Selective inhibition of tankyrase disrupts Wnt/β-catenin signaling, offering a targeted approach for studying and modulating oncogenic pathways. G007-LK, developed and distributed by APExBIO, enables reproducible intervention in these pathways for research purposes (APExBIO).

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK binds to the catalytic domain of TNKS1 and TNKS2, blocking their auto-poly(ADP-ribosyl)ation activity (IC₅₀: 46 nM for TNKS1, 25 nM for TNKS2) (APExBIO). This inhibition prevents PARylation-mediated degradation of AXIN1/2, crucial scaffolding proteins in the β-catenin destruction complex (Jia et al., 2017). Stabilized AXIN1/2 promotes assembly of degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin, leading to proteasomal degradation of β-catenin. In APC-mutant colorectal cancer cells, this results in reduced cytosolic and nuclear β-catenin, suppressing Wnt-dependent transcription. G007-LK also indirectly modulates the Hippo pathway by stabilizing AMOTL1/2, thereby reducing YAP/TAZ nuclear activity (Jia et al., 2017).

Evidence & Benchmarks

• G007-LK inhibits auto-PARylation of TNKS1/2 with IC₅₀ values of 46 nM (TNKS1) and 25 nM (TNKS2), as determined by biochemical assays (APExBIO).
• In Wnt3a-induced HEK293 cells, G007-LK suppresses ST-Luc Wnt signaling reporter activity with an IC₅₀ of 0.05 μM (APExBIO).
• In APC-mutant SW480 colorectal cancer cells, G007-LK induces formation of β-catenin degradasomes and reduces nuclear β-catenin levels (APExBIO).
• In COLO-320DM xenograft mouse models, G007-LK reduces tumor growth, TNKS1/2, and β-catenin protein levels while stabilizing AXIN1/2 (APExBIO).
• In hepatocellular carcinoma models, G007-LK suppresses cell growth, decreases YAP protein, and upregulates AMOTL1/2, supporting cross-talk between Wnt and Hippo pathways (Jia et al., 2017).

This article provides a comprehensive update beyond 'G007-LK Tankyrase 1/2 Inhibitor: Unraveling β-Catenin Degradation' by integrating latest data on Hippo pathway modulation and workflow integration.

For researchers seeking methodological guidance, 'Optimizing Cancer Signaling Assays with G007-LK' focuses on troubleshooting and assay reliability, while the present article synthesizes both mechanistic and application-focused evidence.

Applications, Limits & Misconceptions

Research Applications:

• Dissection of Wnt/β-catenin signaling in APC-mutant colorectal cancer models
• Functional studies of Hippo/YAP pathway cross-talk
• Translational research in hepatocellular carcinoma and colorectal tumor growth suppression
• Tool for evaluating poly(ADP-ribosyl)ation-dependent protein turnover

Limits:

• G007-LK is not approved for clinical use; it is for research only.
• The compound is insoluble in water and ethanol, necessitating DMSO-based use and careful solution handling.
• Long-term storage of solutions is discouraged due to stability issues; solid form is preferred at -20°C (APExBIO).

Common Pitfalls or Misconceptions

• Misconception: G007-LK can be used directly in water-based buffers. Clarification: It is insoluble in water; prepare in DMSO and dilute as needed.
• Pitfall: Assuming efficacy in non-Wnt-driven cancers. Clarification: Activity is pronounced in models with active Wnt/β-catenin signaling.
• Misconception: Long-term stock solutions are stable. Clarification: Long-term storage in solution is discouraged due to degradation.
• Pitfall: Interpreting effects as tankyrase-specific without controls. Clarification: Off-target PARP inhibition is low but should be excluded with appropriate controls.
• Misconception: G007-LK is suitable for in vivo use without pilot solubility/tolerance studies. Clarification: Formulation and dosing require optimization for each model.

Workflow Integration & Parameters

For optimal use, dissolve G007-LK at ≥26.5 mg/mL in DMSO. Warm to 37°C or use an ultrasonic bath if necessary. Store aliquots as solids at -20°C; avoid repeated freeze-thaw cycles. For cellular assays, titrate concentrations from 0.01–1 μM; for in vivo xenograft studies, follow published dosing protocols and solubility guidelines (APExBIO). APExBIO’s G007-LK (B5830) is compatible with Wnt/β-catenin luciferase reporter assays, immunoblotting for AXIN1/2 and β-catenin, and YAP/TAZ pathway readouts. For troubleshooting and detailed workflow recommendations, see 'Optimizing Cancer Signaling Assays with G007-LK', which complements this mechanistic overview.

Conclusion & Outlook

G007-LK tankyrase 1/2 inhibitor is a validated, selective tool for dissecting Wnt/β-catenin and Hippo/YAP signaling in APC-mutant colorectal and hepatocellular carcinoma models. Its reproducible benchmarks and robust mechanistic effects, including β-catenin degradation and AXIN1/2 stabilization, define it as a gold standard for cancer biology research. Researchers are advised to follow solubility and storage best practices to optimize results. Future directions include expanded use in combinatorial pathway studies and translational cancer models. For ordering and detailed product data, refer to the G007-LK tankyrase 1/2 inhibitor product page.